? 關(guān)鍵詞 帕博利珠單抗 司帕生坦 厄貝沙坦 齊泊騰坦 達(dá)格列凈 阿替利珠單抗 貝伐珠單抗 奧妥珠單抗 基因檢測(cè) 格菲妥單抗 賽帕利單抗 ?

#今日行業(yè)熱點(diǎn)#

①The Lancet：Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial 臨床試驗(yàn)：帕博利珠單抗（Pembrolizumab）聯(lián)合化療對(duì)比與化療用于晚期胸膜間皮瘤的比較:一項(xiàng)Ⅲ期、開放標(biāo)簽、隨機(jī)對(duì)照試驗(yàn) DOI: 10.1016/S0140-6736(23)01613-6

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial - The Lancet

②The Lancet：Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial 臨床試驗(yàn)：司帕生坦（Sparsentan）與厄貝沙坦（Irbesartan）用于IgA腎病的療效和安全性比較(PROTECT):一項(xiàng)隨機(jī)、活性藥對(duì)照、Ⅲ期試驗(yàn)的2年結(jié)果 DOI: 10.1016/S0140-6736(23)02302-4

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - The Lancet

③The Lancet：Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial 臨床試驗(yàn)：齊泊騰坦(Zibotentan)聯(lián)合達(dá)格列凈對(duì)比達(dá)格列凈單藥用于慢性腎臟病(ZENITH-CKD)的比較:一項(xiàng)多中心、隨機(jī)、活性藥對(duì)照、Ⅱb期臨床試驗(yàn) DOI: 10.1016/S0140-6736(23)02230-4

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet

④The Lancet Oncology：Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 研究：基于人工智能的病理學(xué)作為肝細(xì)胞癌患者對(duì)阿替利珠單抗-貝伐珠單抗敏感性的生物標(biāo)志物:一項(xiàng)多中心回顧性研究 DOI: 10.1016/S1470-2045(23)00468-0

Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study - The Lancet Oncology

⑤The Lancet Oncology：Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial 臨床數(shù)據(jù)：BTK抑制劑伊布替尼聯(lián)合維奈托克(venetoclax)對(duì)比苯丁酸氮芥聯(lián)合奧妥珠單抗（Obinutuzumab）用于慢性淋巴細(xì)胞白血病(GLOW)的一項(xiàng)多中心、開放標(biāo)簽、隨機(jī)、Ⅲ期試驗(yàn)的4年隨訪 DOI: 10.1016/S1470-2045(23)00452-7

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology

⑥The Lancet Gastroenterology and Hepatology：Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management 綜述：從息肉病綜合征和基因、基因檢測(cè)和臨床管理看胃腸道息肉病領(lǐng)域的最新進(jìn)展和挑戰(zhàn) DOI: 10.1016/S2468-1253(23)00240-6

Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management - The Lancet Gastroenterology & Hepatology

⑦CD20/CD3靶向的T細(xì)胞雙特異性抗體格菲妥單抗（Glofitamab ）獲國家藥監(jiān)局附條件批準(zhǔn)上市，用于復(fù)發(fā)或難治性彌漫大B細(xì)胞淋巴瘤（DLBCL） ⑧JAK1抑制劑烏帕替尼注冊(cè)III期試驗(yàn)，擬評(píng)估用于非節(jié)段性白癜風(fēng)（NSV）的有效性與安全性 ⑨TIGIT抗體Domvanalimab與PD-1抗體賽帕利單抗（Zimberelimab）聯(lián)合鉑類藥物用于轉(zhuǎn)移性胃、胃食管連接部或食管腺癌患者的Ⅱ期EDGE-Gastric臨床結(jié)果積極 ⑩TYK2抑制劑VTX958用于中重度斑塊型銀屑病的Ⅱ期臨床達(dá)到主要終點(diǎn)和所有次要終點(diǎn)，但由于效果未達(dá)到研究?jī)?nèi)部目標(biāo)，此項(xiàng)Ⅱ期試驗(yàn)已被終止 科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！